DIFFERENCES IN ANTITHROMBIN III ACTIVITIES BY ADMINISTRATION METHOD IN CRITICAL PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATION
- 1 August 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Shock
- Vol. 28 (2) , 141-147
- https://doi.org/10.1097/shk.0b013e31803422c4
Abstract
Pharmacokinetic (PK) data for antithrombin III (AT) are limited in the critical patients. We therefore performed PK analysis using a two-compartment model and also examined whether plasma AT activity would change depending on two administration methods, AT agent at 500 U/8 h (divided group) or 1,500 U/24 h (combined group) for 3 days, a regulated dosage for disseminated intravascular coagulation (DIC) treatment in Japan, in critical patients with DIC. Clinical prospective randomized study. A high care unit in a university hospital. Twenty-four consecutive critical patients with DIC. Ages ranged from 34 to 91 years. Acute physiology age and chronic health evaluation II scores were 25 to 35. Antithrombin III activities in the combined group caused remarkable transient increases but returned to near the preadministration level 24 h after the infusion. Antithrombin III level in the divided group showed small elevations on each session; therefore, steady increases were found after serial administrations of the agent. On the third day, AT trough activities in the divided group were significantly higher than those in the combined group (P = 0.005). However, peak AT activities in the combined group after AT administration were higher than those in the divided group throughout the study (P = 0.024). Aggravation of bleeding tendency occurred more frequently in the combined group (P = 0.03). Half-life times on the distribution phase in both groups were remarkably shorter than those of previously reported control in congenital AT deficiency. This suggests an increased vascular permeability in the critical patients in this study. Distribution volume in the patients here increased significantly as compared with the previous controls. This is the first PK report using a two-compartment model to demonstrate that remarkable increases in vascular permeability and distribution volume occur in critical patients with DIC, and if the same dose is administered intermittently in such PK situation, AT administration in divided manner can maintain plasma AT trough activity higher than that in the combined method.Keywords
This publication has 14 references indexed in Scilit:
- SERUM ALBUMIN LEVELS ANTICIPATE ANTITHROMBIN III ACTIVITIES BEFORE AND AFTER ANTITHROMBIN III AGENT IN CRITICAL PATIENTS WITH DISSEMINATED INTRAVASCULAR COAGULATIONShock, 2007
- High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety*Critical Care Medicine, 2006
- Treatment effects of high‐dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulationJournal of Thrombosis and Haemostasis, 2006
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- Antithrombin III in patients with severe sepsis: a pharmacokinetic studyIntensive Care Medicine, 2000
- Criteria for Diagnosis of DIC Based on the Analysis of Clinical and Laboratory Findings in 345 DIC Patients Collected by the Research Committee on DIC in JapanPublished by S. Karger AG ,1983
- Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiencyScandinavian Journal of Clinical and Laboratory Investigation, 1981
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981
- Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administrationEuropean Journal of Clinical Investigation, 1977